UBS analyst Trung Huynh raised the firm’s price target on Amgen (AMGN) to $326 from $315 and keeps a Neutral rating on the shares. UBS forecasts a small beat for Amgen in Q2 results following two solid quarter of beats in the row, the analyst tells investors in a research note. The firm continues to believe the rare disease products could be bumpy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Phase 3 Study on Etelcalcetide: A Potential Game-Changer for Pediatric Kidney Disease
- Amgen’s Phase 2 Asthma Study: A Potential Game-Changer for Rocatinlimab
- Amgen’s Promising Phase 3 Study: Maridebart Cafraglutide for Obesity in Type 2 Diabetes
- Amgen’s Romiplostim Study: A Potential Game-Changer for Chemotherapy Patients
- Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment